Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.
about
Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugatesInvasive Haemophilus influenzae type b disease in the Oxford region (1985-91)Cost benefit analysis of Haemophilus influenzae type b vaccination programme in IsraelMurine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.Active immunization in the United States: developments over the past decade.Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharideMucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescentsWHO policy development processes for a new vaccine: case study of malaria vaccines.Health care budgets and vaccine programs: a time for review and prioritizationBacterial Meningitis after Cochlear Implantation among Children without Polyvalent Conjugate Vaccine: A Brief Report of an Iranian Cohort Study on 371 Cases.Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM₁₉₇ conjugate vaccine.Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya.Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trialsPediatric immunization for the 1990s.Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunityImmune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.The Role of Research in Integrated Health Care Systems: The HMO Research Network.Ozonolysis for selectively depolymerizing polysaccharides containing beta-D-aldosidic linkagesImmunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complexConjugate vaccines and the carriage of Haemophilus influenzae type b.Staphylococcus aureus vaccines: Deviating from the carolDose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trialsAntigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM(197) differs depending on the serotype of the attached polysaccharide.Molecular epidemiology of Haemophilus influenzae type b in the Gambia.Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants.Haemophilus influenzae type bVaccination against Haemophilus influenzae b disease.Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG
P2860
Q24514532-92A37C92-8481-4BA0-991B-5A8923245098Q33623743-65482AD1-7F8D-4925-8652-AA28179E9C4FQ33702129-FFBCBD14-347B-4FC5-B8C1-382EC2137D7EQ33767903-2F141A34-2CF1-4102-B8BB-5693B827C1F0Q33975799-99FA7A17-300E-4A97-8A7A-065F8092EF3AQ34000337-79EAE821-F5B9-4680-A2DF-DCD314ED32F2Q34004276-120CBF45-D3EA-4BB4-AD86-D20CF4BC0677Q34008911-3D313746-1B11-4F4D-BB5E-38C7F9959BAFQ34276706-63F66D4E-EB1C-4534-A98C-C98D7F520E5DQ34648387-9D5BA107-5391-4B57-90B9-E5BEEE984DC7Q34706329-E6A4D589-BFBC-486D-A64D-8BB8C00E3271Q35066102-6B69F614-10D4-4986-B4F7-792B2FADAA11Q35070815-D944ED0D-9F53-49FF-AAD6-2900949FA3F5Q35528932-3C1F85E8-6A51-4947-AC9A-329718F4E2D6Q35839193-033D1358-5223-4532-A885-3013FBB18F86Q35844906-4FF91C4C-E88E-4BC3-9A7A-280F33D826D7Q35874108-F9356461-8ADA-4DCE-A70A-9CF432082590Q36402939-9A2AE7E0-DBD2-462A-A2CC-A8D98213F875Q36480740-9808CA11-BF7C-43D6-8721-3C4F1BE446F8Q36972189-D3A6FA91-1F15-4C41-9962-A991409A07A6Q37062275-1CA74E92-4440-4491-BF68-18B9C89755A8Q37197990-89879A90-C8F8-428A-9CAC-C18B2BF14248Q38009929-BC701813-798C-43ED-9C3A-75BE90B10602Q39776822-60536192-5CD1-4652-BE88-BA3990E74738Q40185271-3D24C60C-CBA2-4C0E-82CE-252663B14EA0Q40703214-A0C7704F-0A05-4E37-AB93-1322160F3FA7Q42584011-3C2C658B-1201-4BFC-877D-49CAEA822D91Q42763070-80D7F95A-C530-4623-BB84-A82C44125BD2Q59134868-73BF9E3C-180D-4944-8317-A1F035E8C583
P2860
Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Efficacy in infancy of oligosa ...... Study Center Pediatrics Group.
@en
type
label
Efficacy in infancy of oligosa ...... Study Center Pediatrics Group.
@en
prefLabel
Efficacy in infancy of oligosa ...... Study Center Pediatrics Group.
@en
P2093
P1476
Efficacy in infancy of oligosa ...... Study Center Pediatrics Group
@en
P2093
E Vittinghoff
H R Shinefield
P304
P356
10.1097/00006454-199102000-00004
P577
1991-02-01T00:00:00Z